| P50 | author | Seok Kyo Seo | Q42862222 |
| | Ellen M Gravallese | Q117258216 |
| P2093 | author name string | Dan Wang | |
| | Jun Xie | |
| | Jae-Hyuck Shim | |
| | Guangping Gao | |
| | Jung-Min Kim | |
| | Phillip W L Tai | |
| | Sachin Chaugule | |
| | Yeon-Suk Yang | |
| | JiHea Kim | |
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling | Q24319108 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels | Q24646235 |
| | Pathogenesis, management and prevention of atypical femoral fractures | Q26824555 |
| | Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas | Q28274710 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee | Q29616160 |
| | Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse | Q33646429 |
| | Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. | Q33901933 |
| | Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions | Q33938435 |
| | The surface chemistry of bone mineral and related calcium phosphates | Q33987319 |
| | The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. | Q34009651 |
| | Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. | Q34132686 |
| | Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment | Q34182079 |
| | Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo | Q34277742 |
| | Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts | Q34679499 |
| | Control of osteoblast function and regulation of bone mass | Q35128237 |
| | The AAV vector toolkit: poised at the clinical crossroads | Q35876224 |
| | Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. | Q36028204 |
| | Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation | Q36580426 |
| | Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. | Q36624790 |
| | Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein | Q36653678 |
| | Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 |
| | Tailoring the AAV vector capsid for gene therapy. | Q37340302 |
| | The advent of AAV9 expands applications for brain and spinal cord gene delivery | Q38004089 |
| | Basic biology of adeno-associated virus (AAV) vectors used in gene therapy | Q38192720 |
| | c-Jun N-Terminal Kinases (JNKs) Are Critical Mediators of Osteoblast Activity In Vivo | Q38754621 |
| | Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity. | Q38809600 |
| | Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes | Q39596327 |
| | Evaluation of Ga-DOTA-(D-Asp)n as bone imaging agents: D-aspartic acid peptides as carriers to bone. | Q42630126 |
| | Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 |
| | Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density | Q43252754 |
| | Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation | Q47131626 |
| | Sema3A regulates bone-mass accrual through sensory innervations. | Q50745844 |
| | Merck &Co. drops osteoporosis drug odanacatib. | Q51452182 |
| | Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. | Q52400421 |
| | A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. | Q54326868 |
| | Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. | Q55033830 |
| | Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 |
| | Effects of denosumab on bone turnover markers in postmenopausal osteoporosis | Q58970691 |
| | Adeno-associated virus vector as a platform for gene therapy delivery | Q64040883 |
| | Ovariectomy-induced bone loss varies among inbred strains of mice | Q81820764 |
| | Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis | Q91621964 |
| | Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold | Q92020402 |
| P921 | main subject | gene silencing | Q1431332 |
| P304 | page(s) | 922-935 | |
| P577 | publication date | 2020-04-18 | |
| P1433 | published in | Molecular Therapy. Methods & Clinical Development | Q27725341 |
| P1476 | title | Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy | |
| P478 | volume | 17 | |